Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Repligen Corp.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The Brussels-based company has leant on its local knowledge to snap up Leuven-headquartered biotech Handl and its proprietary AAV capsid technology platform.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
- Research, Analytical Equipment & Supplies
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Atoll GmBH
- C Technologies, Inc.
- Novozymes Biopharma Sweden AB
- TangenX Technology Corporation